Flexion Therapeutics, Inc. (FLXN)
(Delayed Data from NSDQ)
$10.77 USD
+0.10 (0.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[FLXN]
Reports for Purchase
Showing records 1 - 15 ( 15 total )
Industry: Medical - Drugs
Following Announced Sale to Pacira, Lowering Price Target to $10, Rating to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
Industry: Medical - Drugs
2Q21 Results; Reaffirms 2021 Sales Guidance of $120-$130M; Pipeline on Track; Positive Shoulder OA Data Post-Quarter
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
1Q21 Results; ZILRETTA Launch on Track; Reports Initial Promising Data on FX201; Additional Data Expected in 4Q21
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
Positive Pre-announcement Starts Year With Bullish Tone; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
4Q20 Results; Strong ZILRETTA Fundamentals, Pipeline Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
FX201 Clears Safety Hurdle, Enters Dose-Escalation Phase; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
Energy and Enthusiasm Have Never Been Higher
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
ZILRETTA''s Robust Recovery Continues, Pipeline Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
Reports 3Q20 Results; ZILRETTA Resurgence and Pipeline Remain on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
Solid Fundamentals, Favorable Competitive Dynamics Support Our Bull Thesis
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Industry: Medical - Drugs
ZILRETTA Launch on Track; Pipeline Progressing
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Drugs
2Q20 Results; Resumes FX201 Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Drugs
ZILRETTA''s Robust Rebound Should Continue in 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Industry: Medical - Drugs
Initiating Coverage With a Buy and $25 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
|